Infographic | May 12, 2020

Biologic Drug Product Outsourcing

Source: ISR Reports

In Q4 2019, ISR asked 163 outsourcers of biologic drug product about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated to preferred providers (37%), followed by strategic partnerships (33%). To learn more, follow the link to the Biologic Drug Product CMO Quality Benchmarking report preview.

VIEW THE INFOGRAPHIC!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: